Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Gastric cancer ranks the fourth most prevalent malignancy among men and the seventh among women. In the context of this disease, fibroblast growth factors (FGFs) play a critical role by binding to FGFR, subsequently leading to phosphorylation at intracellular tyrosine residues. This, in turn, triggers downstream signaling activation. In roughly 30% of gastric carcinomas, there is an observable overexpression of the FGFR2 protein. This overexpression correlates positively with scirrhous cancer, a diffuse type of cancer, invasion depth, infiltration type, and a less favorable prognosis. Approximately 5-10% of gastric cancer patients exhibit amplification of FGFR2. Several factors are associated with an elevated risk of developing gastric cancer. These factors encompass dietary elements such as high-salt intake from salt-preserved foods, consumption of N-nitroso compounds from dietary sources, smoking, inadequate intake of vitamins A and C, excessive consumption of smoked or cured foods, insufficient consumption of refrigerated foods, and exposure to contaminated drinking water. Furthermore, an increased body mass index (BMI), higher calorie consumption, gastroesophageal reflux, and smoking are all linked to a heightened risk of adenocarcinomas affecting the distal esophagus, proximal stomach, and junction. The choice of treatment for gastric cancer hinges on the precise preoperative staging. Therapeutic options encompass endoscopic resection for superficial disease confined to the mucosa (< T1b, N0), upfront surgical resection with lymphadenectomy (< T3, any N), neoadjuvant therapy for cases exceeding T2, adjuvant therapy for cases falling within > T1N1 or > T3N0, radiation therapy, or a combination of these modalities for resectable lesions. For individuals with locally advanced unresectable or metastatic disease (T4, any N, or M1), palliative systemic therapy is considered.
• The annual incidence of gastric cancer is 6.9 cases per 100,000 men and women per year.

Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Gastric Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Gastric Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Gastric Cancer, Gastric Cancer market outlook, Gastric Cancer competitive landscape, Gastric Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)